share_log

Transcode Therapeutics | 10-Q: Q1 2024 Earnings Report

Transcode Therapeutics | 10-Q: Q1 2024 Earnings Report

Transcode Therapeutics | 10-Q:2024财年一季报
美股SEC公告 ·  05/15 22:23

Moomoo AI 已提取核心信息

Transcode Therapeutics, a platform delivery company focusing on oncology, reported no income tax benefit or expense for Q1 2024, maintaining a full valuation allowance against its net deferred tax assets due to historical net operating losses. The company is appealing a Nasdaq delisting notice for failing to meet the Minimum Bid Price Requirement, with a hearing scheduled for June 25, 2024. Transcode's lead therapeutic candidate, TTX-MC138, targets miRNA-10b, a master regulator in various cancers. The company received FDA approval to conduct a Phase I/II clinical trial for TTX-MC138, expected to commence mid-2024. Other preclinical stage programs include TTX-siPDL1, TTX-RIGA, TTX-CRISPR, and TTX-mRNA, all utilizing the proprietary TTX delivery mechanism. Transcode's restructuring in December 2023 reduced headcount and prioritized the...Show More
Transcode Therapeutics, a platform delivery company focusing on oncology, reported no income tax benefit or expense for Q1 2024, maintaining a full valuation allowance against its net deferred tax assets due to historical net operating losses. The company is appealing a Nasdaq delisting notice for failing to meet the Minimum Bid Price Requirement, with a hearing scheduled for June 25, 2024. Transcode's lead therapeutic candidate, TTX-MC138, targets miRNA-10b, a master regulator in various cancers. The company received FDA approval to conduct a Phase I/II clinical trial for TTX-MC138, expected to commence mid-2024. Other preclinical stage programs include TTX-siPDL1, TTX-RIGA, TTX-CRISPR, and TTX-mRNA, all utilizing the proprietary TTX delivery mechanism. Transcode's restructuring in December 2023 reduced headcount and prioritized the Phase I clinical trial of TTX-MC138. The company entered a collaboration with Debiopharm to develop targeted mRNA delivery to cancer cells. Despite regaining compliance with Nasdaq's stockholders' equity requirement, Transcode's common stock faces potential delisting due to not meeting the Minimum Bid Price Requirement. Financially, Transcode has not generated revenue from product sales and has incurred significant operating losses. As of March 31, 2024, the company had an accumulated deficit of approximately $49.7 million and cash of $4.9 million, expected to fund operations into Q3 2024. Transcode's future plans include advancing clinical development of TTX-MC138, expanding its product candidate pipeline, and seeking additional funding to support operations.
平台型肿瘤递送公司Transcode Therapeutics报告称,2024年第一季度未获得所得税减免或开支,由于历史净营业亏损,继续针对净递延税资产保持完全减值准备。该公司正在上诉纳斯达克因未达到最低买入价要求而发出的退市通知,听证会定于2024年6月25日举行。Transcode的领先治疗候选药物TTX-MC138针对多种癌症中的主导调节因子miRNA-100亿元。该公司获得了FDA批准,开展TTX-MC138的1/2期临床试验,预计将于2024年中期开始。其他临床前阶段项目包括使用专有TTX递送机制的TTX-siPDL1、TTX-RIGA、TTX-CRISPR和TTX-mRNA。Tra...展开全部
平台型肿瘤递送公司Transcode Therapeutics报告称,2024年第一季度未获得所得税减免或开支,由于历史净营业亏损,继续针对净递延税资产保持完全减值准备。该公司正在上诉纳斯达克因未达到最低买入价要求而发出的退市通知,听证会定于2024年6月25日举行。Transcode的领先治疗候选药物TTX-MC138针对多种癌症中的主导调节因子miRNA-100亿元。该公司获得了FDA批准,开展TTX-MC138的1/2期临床试验,预计将于2024年中期开始。其他临床前阶段项目包括使用专有TTX递送机制的TTX-siPDL1、TTX-RIGA、TTX-CRISPR和TTX-mRNA。Transcode于2023年12月进行了重组,减少了人员规模,将TTX-MC138的1期临床试验作为优先任务。该公司与德必昂合作开发针对癌细胞的靶向mRNA递送。尽管重新符合纳斯达克股东权益要求,但由于未达到最低买入价要求,Transcode的普通股仍面临潜在的退市风险。在财务上,Transcode尚未从产品销售中产生收入,并产生了重大营业亏损。截至2024年3月31日,该公司的累计赤字约为$49.7百万,现金为$4.9百万,预计将资助运营至2024年第3季度。Transcode的未来计划包括推进TTX-MC138的临床开发,扩大其产品候选药物管线,并寻求额外的资金支持运营。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息